SCHEMBL11943832

SCHEMBL11943832

CCCCCCCOc1c(N2CCN(C(=O)c3cccs3)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.49
▸ DCTPP1 Q9H773 3/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ HRH2 P25021 1/20 0.44
▸ HRH1 P35367 1/20 0.44
▸ KCNA5 P22460 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943845 0.86 ALDH1A1 (0.51) ALDH1A1DCTPP1RXFP1SMN1; SMN2KMT2A
SCHEMBL11943848 0.84 ALDH1A1 (0.49) ALDH1A1DCTPP1RXFP1SMN1; SMN2KMT2A
SCHEMBL11943842 0.84 ALDH1A1 (0.50) ALDH1A1DCTPP1RXFP1SMN1; SMN2MEN1
SCHEMBL11943873 0.82 MAPT (0.52) ALDH1A1DCTPP1SMN1; SMN2MEN1KMT2A
SCHEMBL11944990 0.82 MAPT (0.52) ALDH1A1DCTPP1SMN1; SMN2MEN1KMT2A
SCHEMBL11944991 0.82 MAPT (0.52) ALDH1A1DCTPP1SMN1; SMN2MEN1KMT2A
SCHEMBL11943875 0.82 MAPT (0.52) ALDH1A1DCTPP1SMN1; SMN2MEN1KMT2A
SCHEMBL11944993 0.82 MAPT (0.52) ALDH1A1DCTPP1SMN1; SMN2MEN1KMT2A
SCHEMBL11943865 0.82 MAPT (0.52) ALDH1A1DCTPP1SMN1; SMN2MEN1KMT2A
SCHEMBL11943872 0.81 MAPT (0.52) ALDH1A1DCTPP1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885DCTPP1 625/4885RXFP1 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback